Physician profile
John Zade
NPI 1962931964
$5,807.64
in general payments reported to CMS, 2019-2025
27 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805 · 2020: $92.19 · 2021: $826 · 2022: $1,519 · 2023: $1,531 · 2024: $758 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,475.41 | 2019-2025 | Botox, Rinvoq, Skyrizi |
| Lilly USA, LLC | $393.10 | 2021-2024 | Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $382.98 | 2021-2024 | Winlevi, Blu-U, Odomzo |
| Amgen INC. | $375.03 | 2023-2025 | Otezla, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $360.44 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $341.41 | 2019-2023 | Libtayo |
| Janssen Biotech, INC. | $293.75 | 2021-2024 | Tremfya |
| Allergan, INC. | $281.28 | 2019 | |
| Genzyme Corporation | $265.95 | 2019-2023 | |
| Pfizer INC. | $238.15 | 2019-2024 | |
| Incyte Corporation | $215.94 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $155.09 | 2023-2024 | Zoryve |
| Merz North America, INC. | $145.45 | 2019 | |
| Galderma Laboratories, L.P. | $140.36 | 2021 | |
| Dermavant Sciences, INC. | $120.52 | 2023-2024 | Vtama |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $97.23 | 2022-2025 | Bimzelx |
| Genentech USA, INC. | $95.01 | 2021-2022 | |
| Almirall LLC | $92.03 | 2021-2023 | Klisyri |
| Leo Pharma INC. | $88.27 | 2022-2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $75.85 | 2021-2023 | Jublia |
| Biofrontera INC. | $36.86 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.04 | 2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $26.55 | 2023 | |
| Verrica Pharmaceuticals INC. | $22.74 | 2023 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.55 | 2024 | Spevigo |
| Kyowa Kirin, INC. | $20.44 | 2019 | |
| Journey Medical Corporation | $17.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Zade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.